Does increased urinary interleukin-1 receptor antagonist/interleukin- 1β ratio indicate good prognosis in renal transplant recipients?

Transplantation

Volumn 66, Issue 8, 1998, Pages 1909-1014

  Teppo, Anna Maija ^a   Honkanen, Eero ^a   Ahonen, Juhani ^a   Gronhagen Riska, Carola ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; C REACTIVE PROTEIN; CREATININE; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1; SIALOGLYCOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; URINARY EXCRETION; URINE LEVEL; BLOOD; CIRCADIAN RHYTHM; GRAFT REJECTION; GRAFT SURVIVAL; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE PERIOD; PROGNOSIS; REFERENCE VALUE; URINE;

ADULT; C-REACTIVE PROTEIN; CIRCADIAN RHYTHM; CREATININE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; REFERENCE VALUES; SIALOGLYCOPROTEINS;

EID: 0032573019     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histological diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
2. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106.
3. Loong CC, Chen A, Lui WY, et al. Expression of cytokines, growth factors, and adhesion molecules in rejecting human renal allograft. Transplant Proc 1996; 38: 1445.
4. Maury CPJ, Teppo A-M. Serum immunoreactive interleukin-1 in renal transplant recipients. Transplant Proc 1987; 19: 4349.
5. Suthanthiran M. Acute rejection of renal allografts: mechanistic insights and therapeutic options. Kidney Int 1997; 51: 1289.
6. Schena FP. New insights into therapy with monoclonal antibodies in allograft transplantation. Nephrol Dial Transplant 1997; 12: 55.
7. Dripps DJ, Verderber E, Ng RK, et al. Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. J Biol Chem 1991; 266: 1.
8. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167.
9. Ferretti M, Casini-Raggi V, Pizarro TT, et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994; 94: 449.
10. Miller LC, Lynch EA, Isa S, et al. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993; 341: 146.
11. Bevan S, Raynes JG. IL-1 receptor antagonist regulation of acute phase protein synthesis in human hepatoma cells. J Immunol 1991; 147: 2574.
12. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Am Soc Hematol 1991; 15: 1915.
13. McCarthy PL, Williams L, Harris-Bacile M, et al. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus- host disease. Transplantation 1996; 62: 626.
14. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342.
15. Ohlsson K, Björk P, Bergenfeld M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550.
16. Cominelli F, Nast CC, Clark BD, et al. Interleukin-1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972.
17. Dana MR, Yamada J, Streinlein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation 1997; 63: 1501.
18. Oliveira JGG, Xavier P, Neto S, et al. Monocytes-macrophages and cytokines/chemokines in fine-needle aspiration biopsy cultures. Transplantation 1998; 63: 1751.
19. Lalla MLT, Eklund B, Ahonen J. The clinical significance of serum C-reactive protein after renal transplantation. Transplant Proc 1988; 20: 402.
20. Maury CPJ, Teppo A-M. Comparative study of serum amyloid A related protein (SAA), C-reactive protein, and beta 2 microglobulin as markers of renal allograft rejection. Clin Nephrol 1984; 22: 284.
21. Harris KP, Digard NJ, Lee HA. Serum C-reactive protein: a useful and economical marker of immune activation in renal transplantation. Transplantation 1996; 61: 1593.
22. Pasternack A, Virolainen M, Häyry P. Fine needle aspiration biopsy in the diagnosis of human renal allograft rejection. J Urol 1973; 109: 167.
23. Fischer E, vanZee KJ, Marano MA, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Am Soc Hematol 1992; 79: 2196.
24. Donati D, Degiannis D, Mazzola E, et al. Interleukin-1 receptors and receptor antagonist in haemodialysis. Nephrol Dial Transplant 1997; 12: 111.
25. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423.
26. Balavoine J-F, deRochemonteix B, Williamson K, et al. Prostaglandin E and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 1986; 78: 1120.
27. Prieur A-M, Kaufmann A-M, Griscelli C, Dayer J-M. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987; 2: 1240.
28. Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993; 150: 4687.
29. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992; 89: 4076.
30. Krzesicki RF, Hatfield CA, Bienkowski MJ, et al. Regulation of expression of IL-1 receptor antagonist in human synovial and dermal fibroblasts. J Immunol 1993; 150: 4008.
31. Turner M, Chantry D, Katrikis P, et al. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-β. Eur J Immunol 1991; 21: 1635.
32. Wahl SM, Costa GL, Corcoran M, et al. Transforming growth factor-β mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993; 150: 3553.
33. Kumar S, Millis AJT, Baglioni C. Expression of interleukin 1 inducible genes and production of interleukin 1 by aging fibroblasts. Proc Natl Acad Sci USA 1992; 89: 4683.
34. McAdam KPWJ, Li J, Knowles J, et al. The biology of SAA: identification of the inducer, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies. Ann NY Acad Sci 1982; 389: 126.
35. Raynes JG, Eagling S, McAdam KPWJ. Acute phase protein synthesis in hepatoma cells: differential regulation of SAA and haptoglobin by IL-1 and IL-6. Clin Exp Immunol 1991; 84: 488.
36. Maury CPJ, Teppo A-M, Aklund B, Ahonen J. Serum amyloid A protein: a sensitive indicator of renal allograft rejection in man. Transplantation 1983; 36: 501.
37. Cominelli F, Pizarro TT. Interleukin-1 receptor antagonist: a "novel" acute phase protein with anti-inflammatory activities. J Clin Invest 1997; 99: 2813.
38. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin-1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99: 2930.
39. Suzuki H, Takomura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995; 38: 1055.
40. Gabay C, Gay-Croisier F, Roux-Lombard P, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/ dermatomyositis. Arthritis Rheum 1994; 12: 1744.
41. Maury CPJ, Teppo A-M, Wegelius O. Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1982; 41: 268.
42. Brown Z, Stricter RM, Neild GH, et al. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int 1992; 42: 95.
43. Fricke H, Endisch G, Borgmann S. Allelic polymorphism in IL-1β and IL-1ra genes in ANCA vasculitis patients [Abstract]. J Am Soc Nephrol 1997; 8: 535A.
44. McCarthy M. Gene therapy for rheumatoid arthritis starts clinical trials. Lancet 1996; 348: 323. 44.
45. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331.